Detalhe da pesquisa
1.
The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia.
Neurobiol Dis
; 118: 64-75, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29936234
2.
Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease.
Brain Behav Immun
; 57: 94-105, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27318096
3.
Comparative global analysis of stroke rehabilitation recommendations across income levels.
J Clin Epidemiol
; 170: 111334, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38548231
4.
CB2 Receptors and Neuron-Glia Interactions Modulate Neurotoxicity Generated by MAGL Inhibition.
Biomolecules
; 10(8)2020 08 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32824740
5.
Target-enriched sequencing of chromosome 17q21.31 in sporadic tauopathies reveals no candidate variants.
Neurobiol Aging
; 66: 177.e7-177.e10, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29398119
6.
GPR55: A therapeutic target for Parkinson's disease?
Neuropharmacology
; 125: 319-332, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28807673
7.
Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease.
Neuropharmacology
; 113(Pt A): 110-123, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27693549
8.
Neuroprotective Effect of JZL184 in MPP(+)-Treated SH-SY5Y Cells Through CB2 Receptors.
Mol Neurobiol
; 53(4): 2312-9, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25976369